Results 111 to 120 of about 22,236,668 (323)
Degradation mechanism of the von Willebrand factor A2 domain by nattokinase
Nattokinase, a natto‐derived protease, exhibits potent antithrombotic effects. This study demonstrates that nattokinase directly cleaves the von Willebrand factor (vWF) A2 domain in vitro. Unlike the native regulator ADAMTS13, nattokinase degrades folded vWF independently of shear stress.
Ryuichi Hyakumoto +3 more
wiley +1 more source
Assessing Treatment Efficacy for Dermatologic Immune-Related Adverse Events: A Systematic Review
The management of dermatologic immune–related adverse events (D-irAEs) remains inconsistent owing to variability in treatment responses and a lack of standardized guidelines.
Christian L. Bailey-Burke +4 more
doaj +1 more source
Immune checkpoint inhibitors are novel biologic agents to treat cancer by inhibiting the regulatory interactions that limit T cell cytotoxicity to tumours. Current agents target either CTLA-4 or the PD-1/PD-L1 axis.
Sophia C. Weinmann, D. Pisetsky
semanticscholar +1 more source
Drug-related, Treatment-Emergent Adverse Events (TEAEs) that occurred during the Open-Label Treatment Period.
Virginia Kimonis (7418696) +4 more
core +1 more source
Prinum non nocere: thoughts on the need to develop an 'adverse events' register for complementary and alternative therapies [PDF]
Building a body of knowledge to support the eff|cacy and practice of complementary and alternative therapies is an imperative that should be fully embraced by all those involved.
Biley, Francis, Francis C. Biley
core +1 more source
Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley +1 more source
Treatment-emergent adverse events occurring in ≥ 5% of patients in the etelcalcetide arms, adverse events leading to discontinuation, and serious adverse events.
Glenn M. Chertow (2967792) +6 more
core +1 more source
Immune-related adverse events.
Immune-related adverse events.
Yuji Miyoshi (3172629) +5 more
core +1 more source
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source
Adverse Events from Emollient Use in Eczema: A Restricted Review of Published Data
Atopic dermatitis/eczema is a chronic inflammatory skin condition, and emollients are the first-line treatment. Despite their widespread use, there is uncertainty about the frequency and type of adverse events associated with different emollients.
Alisha Bhanot +2 more
doaj +1 more source

